Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MECLOFENAMATE SODIUM vs ACULAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
Relief of mild to moderate acute pain,Treatment of primary dysmenorrhea,Management of osteoarthritis,Management of rheumatoid arthritis
Treatment of postoperative inflammation in patients who have undergone cataract extraction,Relief of ocular itching due to seasonal allergic conjunctivitis
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Terminal half-life: 1.8 hours (ketorolac tromethamine); clinical context: short half-life supports dosing every 6 hours for acute pain, but prolonged in elderly or renal impairment (↑ to 5-6 hours, thus dose reduction required).
Primarily hepatic via cytochrome P450 enzymes, including CYP2C9 and CYP3A4.
Hepatic metabolism primarily via cytochrome P450 2C9 (CYP2C9).
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Renal: ~80% as unchanged drug and glucuronide conjugates; biliary/fecal: ~20%
>99% (primarily to albumin)
99% bound; primary binding protein: albumin.
0.5-1.0 L/kg (indicates extensive tissue distribution)
0.11-0.25 L/kg; clinical meaning: low Vd indicates primarily confined to extracellular compartment (plasma and interstitial fluid), minimal tissue penetration.
100% (oral, well absorbed)
Ophthalmic: ~2% systemic absorption after topical instillation (due to corneal permeability and nasolacrimal drainage); oral formulation not used for Acular (ophthalmic only).
e GFR 30-59 m L/min: use with caution, reduce dose by 50%; e GFR <30 m L/min: contraindicated.
No dosage adjustment required for renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
No dosage adjustment required for hepatic impairment.
Not recommended for children under 14 years; for adolescents ≥14 years, same as adult dosing.
Safety and efficacy in pediatric patients have not been established; use not recommended.
Initiate at lowest effective dose (50 mg twice daily); monitor renal function and GI bleeding risk.
No specific dosage adjustment required; use same dosing as for younger adults.
NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. Meclofenamate is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
No FDA boxed warning.
Cardiovascular thrombotic events,Gastrointestinal bleeding, ulceration, and perforation,Hypertension and edema,Renal toxicity,Anaphylactoid reactions,Exacerbation of asthma,Hematologic toxicity including anemia,Hepatic enzyme elevations
May increase bleeding time due to inhibition of platelet aggregation; use with caution in patients with known bleeding tendencies or those receiving other medications that may prolong bleeding time.,May cause corneal effects including keratitis and corneal thinning; discontinue if corneal epithelial breakdown occurs.,Use with caution in patients with prior sensitivity to aspirin, phenylacetic acid derivatives, or other NSAIDs.,May delay wound healing or exacerbate infections; avoid use in patients with active epithelial herpes simplex keratitis.
Hypersensitivity to meclofenamate or any other NSAID,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Perioperative pain in setting of CABG surgery,Active peptic ulcer disease or gastrointestinal bleeding
Hypersensitivity to ketorolac tromethamine or any component of the formulation,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Active epithelial herpes simplex keratitis,Late pregnancy (third trimester) due to risk of premature closure of ductus arteriosus
Avoid high-fat meals as they may delay absorption. Limit salt intake to reduce fluid retention. Do not consume alcohol as it increases the risk of GI bleeding. Meclofenamate may decrease the effectiveness of diuretics and antihypertensive medications when taken with potassium-rich foods; monitor potassium levels.
No known food interactions. Avoid alcohol if concomitant oral NSAIDs are used due to increased risk of gastrointestinal bleeding, but this is not specific to ophthalmic use.
Avoid in 1st and 2nd trimester; contraindicated in 3rd trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Associated with cardiovascular malformations if used in 1st trimester.
Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairment in the third trimester. First and second trimester use should be avoided unless clearly needed. The potential benefits should be weighed against the risks.
Excreted into breast milk in small amounts; M/P ratio not established. Use caution due to potential adverse effects in neonates (e.g., gastrointestinal bleeding, platelet dysfunction).
Ketorolac is excreted in human milk at low levels. The M/P ratio is not well defined. Due to potential adverse effects in nursing infants, caution is advised. Use only if clearly indicated and consider alternative agents.
Increased plasma volume may require dose adjustments in 2nd and 3rd trimesters, but specific studies lacking; generally avoid use. If necessary, use lowest effective dose for shortest duration.
No specific dose adjustments are recommended for pregnancy; however, use the lowest effective dose for the shortest duration due to potential fetal risks. Physiological changes in pregnancy (increased volume of distribution, renal clearance) may alter pharmacokinetics, but no formal studies justify dose modification.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) used for mild to moderate pain, dysmenorrhea, and inflammatory arthropathies. It has a higher incidence of gastrointestinal (GI) side effects, especially diarrhea, which can be dose-limiting. Monitor renal function and blood pressure, as it may cause fluid retention and worsening of hypertension. Use with caution in patients with a history of peptic ulcer disease or bleeding disorders. It is contraindicated in perioperative pain in coronary artery bypass graft (CABG) surgery.
ACULAR (ketorolac tromethamine ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) used for ocular inflammation. Avoid concomitant use with other NSAIDs or corticosteroids due to increased risk of corneal adverse events. Use with caution in patients with bleeding disorders or those on anticoagulants, as it may increase bleeding tendency. Monitor for corneal toxicity, especially in patients with compromised corneal integrity. Ensure proper storage at room temperature and discard if solution changes color or becomes cloudy.
Take with food or milk to reduce stomach upset.,Avoid alcohol and aspirin while taking this medication.,Report signs of GI bleeding (black, tarry stools; blood in vomit) immediately.,May cause diarrhea; notify your doctor if it becomes severe or persistent.,Do not take with other NSAIDs without consulting your doctor.,Stay hydrated, but avoid excessive salt intake to prevent fluid retention.,Inform your doctor if you have kidney disease, high blood pressure, or a history of stomach ulcers.,Do not use during pregnancy, especially in the third trimester.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1 minute after instillation to reduce systemic absorption.,Do not use while wearing soft contact lenses, as the preservative may be absorbed.,Report any signs of corneal problems such as pain, redness, or vision changes immediately.,Use exactly as prescribed and do not share the medication with others.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MECLOFENAMATE SODIUM vs ACULAR, answered by our medical review team.
MECLOFENAMATE SODIUM is a NSAID that works by Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.. ACULAR is a NSAID Ophthalmic that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MECLOFENAMATE SODIUM and ACULAR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MECLOFENAMATE SODIUM is: 50 mg or 100 mg orally three times daily; maximum 400 mg/day.. The standard adult dose of ACULAR is: One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MECLOFENAMATE SODIUM and ACULAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MECLOFENAMATE SODIUM is classified as Category C. Avoid in 1st and 2nd trimester; contraindicated in 3rd trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Associated w. ACULAR is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairm. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.